ALNY - Alnylam Pharmaceuticals Stock Trading

There's a number of upcoming catalysts in the liver disease treatment space, prompting Needham to update its takes on drugmakers targeting the diseases. More news on: Intercept Pharmaceuticals, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Inc., Healthcare stocks news, Notable Calls ...

− Long-Term Givosiran Dosing Showed Sustained Reduction in Annualized Rate of Composite Porphyria Attacks (AAR) With a Median AAR of Zero and Over 60 Percent of Patients Attack-Free in the Open-Label Extension Period − − Safety Profile Consistent With That Observed...

After many long years as a clinical-stage biotech, successful new drugs are beginning to pour out of Alnylam (NASDAQ: ALNY) . The FDA's currently reviewing the third new drug application from the biotech in as many years. Unfortunately for bargain shoppers, Alnylam's string of successes hasn...